



ASX Announcement

26 October 2021

AnteoTech builds executive management for growth with key new appointments

Highlights

- ❖ **Three industry experienced executives join AnteoTech**
 - **Mr Ian Steinhardt - Head of Market Operations – Life Sciences**
 - **Mr Pierre Nathie - Head of Products & Services – Life Sciences**
 - **Mr Tim Pritchard - CFO and Company Secretary**
- ❖ **The strengthened management team is well-positioned to drive and deliver the Company's growth strategy.**

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to announce three new senior appointments. The appointments strengthen the Company's leadership team at a time when the Company is rapidly growing its Life Science distributor base, completing regulatory approvals for its in-vitro diagnostics platform, EuGeni, throughout Europe and South East Asia, and preparing for North American market entry.

Joining AnteoTech on 6 December as **Head of Market Operations – Life Sciences, Ian Steinhardt** will be responsible for executing the Company's global sales and distribution strategy across the Life Sciences division, focusing on the EuGeni Rapid Diagnostic platform. A veteran of the diagnostic, life science and biotech sectors, Ian has over 30 years' experience in managing organisations both in Australia, Asia Pacific and Europe, with a proven track record in sales and marketing and subsequent revenue growth across diagnostic and life science product portfolios. Ian has worked in sales and marketing roles for Sanofi Diagnostics Pasteur and most recently as Enterprise Account Manager for Abbott Diagnostics in Australia.

Pierre Nathie joins AnteoTech as **Head of Product & Services – Life Sciences** and will be charged with the development of the Company's global product marketing strategy across Assay Development (EuGeni), Raw Materials (AnteoBind) and Assay Services. Critically, Pierre will take responsibility for planning and commercial execution of new products including new tests on the EuGeni platform and the associated validation and regulatory cycles of all products. With 25 years' experience in executing and implementing international IVD launch strategies, Pierre has delivered multiple IVD strategic products and managed go-to-market cycles, from initial product concept up to "ready-to-launch" stage. In addition, he has extensive hands-on experience in the selection and performance management of IVD distribution partners in the US, Europe and China. Pierre has held senior positions within BD Diagnostics in Paris and the United Kingdom, most recently, he held the position of Business Development Manager for Universal Biosensors in Melbourne and Managing Director of Med2Mark. Pierre will join AnteoTech on the 8th of November 2021.

Mr Tim Pritchard will commence as **Chief Financial Officer and Company Secretary**, on 1 November, taking over from Mr Duncan Cornish. Duncan will continue in the role of Company Secretary until the end of November 2021 in order to effect a handover. The Board wishes to express its thanks to Duncan, who has been with the Company since early 2019 and wishes him every success in his future endeavours.

Tim has over 25 years' of management experience in finance, accounting, consulting, project management and information technology. In addition to extensive accounting experience, he has led several successful business transformation and system implementation assignments that have resulted in significantly improved financial processes and business systems.

Before joining AnteoTech, Tim was engaged as the Chief Financial Officer and Company Secretary of Leaf Resources, an ASX listed biotechnology company and prior to that, as Chief Financial Officer and Company Secretary of ReNu Energy, an ASX listed renewable energy company.

Tim has a double degree in Accounting and Computing as well as a Master of Commerce and a Master of Information Technology. Tim has returned to work in an area he is passionate about after a brief experience in the education sector.

AnteoTech CEO Derek Thomson commented: "The appointment of Ian, Pierre and Tim strengthen the executive team and brings a breadth of experience, industry knowledge and senior leadership that will help drive the next phase of AnteoTech's growth strategy. The success of the new executive leadership team and, therefore, the Company's success rests on our ability to appropriately leverage these skills within a proven high performing business and technical team. A critical success platform for the new executive team will be continued effective guidance, mentoring and support delivered through the strong relationship with the existing Chair and board members."

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn.

Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Latest News** bulletin, our email alert service.

